GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey

Basit Öğe Kaydı
dc.authoridAkar, Servet/0000-0002-3734-1242
dc.contributor.authorAkar, Servet
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorDalkilic, Ediz
dc.contributor.authorEmmungil, Hakan
dc.contributor.authorAziz, Ayten
dc.contributor.authorEsen, Yasemin
dc.contributor.authorKoc, Tuba
dc.date.accessioned2024-06-12T10:54:06Z
dc.date.available2024-06-12T10:54:06Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAim: To evaluate the retention rate of golimumab (GLM) in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (ax-SpA). Materials & methods: Patients had received/were receiving GLM as their first or second biological drug for at least 3 months. We recorded demographic and clinical data, data on drug continuation and disease activity. Patients were classified as biologic-naive and biologic-experienced. Results: The study included 60 RA and 269 ax-SpA patients. At month 24, the retention rates were 67.2 and 57.1% (biologic-naive and biologic-experienced RA) and 74.8 and 80.4% (anti-TNF-naive and -experienced ax-SpA). No significant differences in retention were observed between the biologic-naive and -experienced groups for either disease. Conclusion: The results of this study confirm the effectiveness of GLM in the treatment of RA and axSpA with good retention rates at 2 years in a real-world setting in Turkey.en_US
dc.identifier.doi10.2217/imt-2020-0296
dc.identifier.endpage850en_US
dc.identifier.issn1750-743X
dc.identifier.issn1750-7448
dc.identifier.issue10en_US
dc.identifier.pmid33955239en_US
dc.identifier.scopus2-s2.0-85107606413en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage841en_US
dc.identifier.urihttps://doi.org/10.2217/imt-2020-0296
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18921
dc.identifier.volume13en_US
dc.identifier.wosWOS:000647582000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofImmunotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAxial Spondyloarthritisen_US
dc.subjectBiologicen_US
dc.subjectEfficacyen_US
dc.subjectGolimumaben_US
dc.subjectRetentionen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectTNF-? Inhibitoren_US
dc.titleGO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu